increas
preval
natur
product
includ
marin
product
use
improv
bodi
function
manag
variou
ailment
due
divers
pharmacolog
although
limit
spars
clinic
evid
applic
particular
lack
data
molecular
target
mechan
action
pharmacokinet
pk
mainli
focus
absorpt
distribut
metabol
excret
adm
toxicolog
natur
hand
mani
natur
product
abil
regul
import
drugmetabol
enzym
drug
transport
cytochrom
enzym
cyp
pglycoprotein
rais
safeti
concern
regard
use
natur
product
due
modulatori
effect
activ
express
drugmetabol
enzym
drug
transport
result
potenti
harm
drug
interact
eventu
advers
drug
human
cyp
superfamili
consist
function
gene
oxid
drug
clinic
human
subfamili
contain
four
member
abund
enzym
liver
importantli
predispos
induct
inhibit
expos
number
endogen
exogen
factor
probabl
result
alter
pk
profil
victim
drug
advers
drug
reaction
particular
drug
narrow
therapeut
index
digoxin
warfarin
rat
subfamili
contain
rat
ident
amino
acid
sequenc
human
share
lot
substrat
specif
inhibitor
select
cardiovascular
diseas
cvd
coronari
heart
diseas
stroke
lead
caus
death
throughout
world
million
peopl
die
cvd
account
global
million
death
result
coronari
heart
diseas
million
death
due
incid
cvd
increas
expos
individu
famili
societi
great
burden
pathogenesi
cvd
complic
oxid
stress
propos
causal
factor
reduc
oxid
stress
report
promis
strategi
treatment
number
natur
product
show
potent
antioxid
effect
coadministr
natur
product
cardiovascular
drug
gain
increas
popular
effect
although
lack
systemat
preclin
clinic
data
pk
molecular
target
mechan
action
marin
organ
attract
sourc
drug
develop
numer
compound
isol
marin
organ
wide
rang
pharmacolog
activ
includ
antioxid
antiinflammatori
anticanc
xyloket
b
xkb
figur
novel
marin
compound
isol
mangrov
fungu
xylaria
sp
potent
antioxid
neuroprotect
cardioprotect
found
xkb
relax
effect
blood
vessel
protect
endotheli
cell
oxid
injuri
induc
oxid
lowdens
directli
scaveng
free
radicalgener
compound
protect
cell
depriv
strong
inhibitori
effect
lcalcium
potent
antioxid
effect
xkb
suggest
promis
agent
treatment
oxid
stressassoci
condit
cvd
establish
doserespons
dosetox
relationship
xkb
investig
metabol
pk
rat
vivo
plasma
pk
xkb
follow
twocompart
model
distribut
phase
elimin
xkb
show
short
elimin
halflif
minut
suggest
rapidli
distribut
bodi
also
rapidli
elimin
howev
molecular
target
respons
xkb
treatment
effect
xkb
regul
drugmetabol
enzym
unknown
present
studi
order
investig
molecular
target
xkb
predict
target
use
bioinformat
platform
analyz
interact
xkb
rat
use
homolog
model
follow
molecular
dock
examin
effect
oral
xkb
activ
express
hepat
rat
use
midazolam
model
substrat
interactom
xkb
predict
use
ddicpi
tool
webbas
server
predict
interact
via
protein
target
obtain
thirdparti
protein
structur
databas
name
total
protein
data
bank
pdb
entri
human
protein
avail
pdbbind
total
nonredund
pdb
correspond
ligand
bind
pocket
identifi
resolut
less
dock
box
pocket
defin
expand
circumscrib
cube
pocket
margin
six
direct
front
back
left
right
prepar
xkb
twodimension
structur
xkb
download
pubchem
hydrogen
gasteig
charg
ad
file
format
transform
use
vega
zz
dock
program
autodock
use
dock
xkb
molecul
pocket
gener
score
vector
dimens
z
score
calcul
use
methodolog
describ
herein
empir
threshold
z
score
set
indic
bind
xkb
target
like
true
follow
target
predict
databas
annot
visual
integr
discoveri
version
david
http
davidabccncifcrfgov
use
provid
biolog
function
interpret
potenti
target
xkb
deriv
ddicpi
protein
id
target
uniprotkb
nation
center
biotechnolog
inform
sourc
convert
gene
list
use
gene
id
convers
tool
david
david
add
biolog
function
annot
includ
gene
ontolog
pathway
interact
function
group
gene
ie
cluster
diseas
associ
deriv
main
public
data
sourc
gene
interest
visual
use
biocarta
kyoto
encyclopedia
gene
genom
pathway
map
highest
classif
stringenc
select
function
annot
cluster
enrich
score
fisher
exact
test
pvalu
correspond
fals
discoveri
rate
calcul
identifi
functionalrel
gene
group
significantli
enrich
target
list
signific
enrich
gene
group
could
provid
clue
xkb
interact
molecular
target
systemat
way
employ
discoveri
studio
program
design
accelri
inc
san
diego
ca
usa
dock
xkb
midazolam
ketoconazol
probucol
activ
site
human
rat
homolog
model
previous
modif
due
lack
avail
crystal
structur
rat
hepat
built
homolog
model
base
report
human
crystal
structur
pdb
id
http
wwwrcsborgpdb
establish
homolog
model
rat
hepat
first
retriev
rat
sequenc
nation
center
biotechnolog
inform
ncbi
refer
sequenc
http
wwwncbinlmnihgovprotein
align
rat
sequenc
base
templat
human
follow
establish
homolog
model
human
rat
homolog
model
clean
modifi
prepar
prepar
xkb
midazolam
ketoconazol
probucol
duplic
chemic
structur
delet
ioniz
chang
tautom
isom
gener
lipinski
filter
threedimension
gener
set
true
ligand
prepar
xkb
midazolam
ketoconazol
probucol
dock
activ
site
human
rat
homolog
model
electrostat
energi
van
der
waal
forc
consid
dock
process
harmon
potenti
forc
constant
kcalmol
appli
outsid
grid
use
discoveri
studio
program
design
accelri
inc
adm
toxic
admet
profil
xkb
midazolam
ketoconazol
probucol
predict
briefli
chemic
structur
xkb
midazolam
ketoconazol
probucol
retriev
pubchem
databas
figur
structur
introduc
discoveri
studio
program
prepar
prepar
structur
duplic
chemic
structur
delet
ioniz
chang
tautom
isom
gener
lipinski
filter
threedimension
gener
set
true
follow
prepar
structur
xkb
midazolam
ketoconazol
probucol
subject
admet
evalu
use
admet
predictor
modul
paramet
includ
solubl
absorpt
permeabl
across
barrier
interact
hepatotox
plasma
protein
bind
predict
four
differ
admet
absorpt
level
rang
indic
good
moder
low
low
absorpt
respect
admet
aqueou
solubl
level
classifi
extrem
low
low
possibl
ye
low
ye
good
ye
optim
solubl
warn
molecul
one
unknown
type
admet
barrier
permeabl
six
differ
level
includ
high
high
medium
low
undefin
warn
molecul
one
unknown
alogp
calcul
two
predict
class
admet
ligand
ie
noninhibitor
inhibitor
admet
hepatotox
categor
nontox
toxic
effect
three
differ
admet
plasma
protein
bind
level
ie
bind
bind
bind
xkb
puriti
synthes
sun
yatsen
univers
guangzhou
peopl
republ
china
nicotinamid
adenin
dinucleotid
phosphat
nadph
midazolam
purchas
sigmaaldrich
st
loui
mo
usa
ketoconazol
obtain
nanj
pharmaceut
co
baijingyu
peopl
republ
china
catalog
number
midazolam
purchas
cayman
chemic
co
ann
arbor
mi
usa
midazolam
inject
sourc
pharmaceut
group
co
ltd
jiangsu
nhwa
jiangsu
peopl
republ
china
diazepam
inject
obtain
amino
acid
co
ltd
tianjin
jin
yao
tianjin
peopl
republ
china
catalog
number
assay
kit
purchas
promega
madison
wi
usa
clariti
western
enhanc
chemiluminesc
ecl
substrat
obtain
biorad
laboratori
hercul
ca
usa
primari
antibodi
rat
purchas
merck
millipor
darmstadt
germani
gadph
antirabbit
immunoglobulin
g
horseradish
peroxidaselink
antibodi
purchas
cell
signal
technolog
boston
usa
highperform
liquid
chromatographi
hplc
grade
acetonitril
ammonium
acet
obtain
merck
darmstadt
germani
ultrapur
water
prepar
laboratori
use
arium
system
sartoriu
corpor
ny
usa
healthi
male
spraguedawley
rat
weigh
g
age
month
purchas
guangdong
medic
laboratori
anim
center
guangzhou
peopl
republ
china
rat
hous
accredit
anim
hous
facil
control
temperatur
darklight
cycl
anim
allow
acclimat
day
prior
experi
experi
conduct
accord
guidelin
anim
care
use
peopl
republ
china
approv
anim
ethic
committe
chines
academi
medic
scienc
beij
peopl
republ
china
anim
randomli
divid
five
group
treat
intraperiton
daili
salin
blank
control
soybean
oil
vehicl
ketoconazol
mgkg
posit
control
xkb
mgkg
consecut
day
anim
free
access
standard
laboratori
food
water
order
reduc
intestin
content
anim
fast
overnight
termin
studi
midazolam
mgkg
administ
oral
hour
last
dose
xkb
blood
sampl
collect
post
ocular
vein
minut
administr
midazolam
blood
sampl
immedi
centrifug
g
minut
obtain
plasma
store
analysi
anim
euthan
cervic
disloc
blood
collect
liver
sampl
collect
assess
activ
express
rat
liver
microsom
prepar
previous
briefli
liver
tissu
collect
wash
icecold
kcl
buffer
ph
tissu
becam
pale
whitish
blot
dri
weigh
subsequ
step
perform
liver
sampl
homogen
three
volum
buffer
ph
use
tissu
homogen
liver
homogen
centrifug
g
minut
supernat
collect
centrifug
g
minut
supernat
thereaft
decant
microsom
pellet
resuspend
homogen
buffer
centrifug
g
minut
remov
hemoglobin
rat
liver
microsom
resuspend
sodium
phosphat
buffer
mm
ethylenediamin
tetraacet
acid
mm
dithiothreitol
glycerol
ph
store
analysi
protein
concentr
microsom
sampl
determin
use
bicinchonin
acid
protein
assay
pierc
chemic
rockford
il
usa
bovin
serum
albumin
standard
plasma
concentr
midazolam
metabolit
measur
hplc
previous
slight
modif
hplc
method
valid
prior
determin
plasma
pk
midazolam
per
intern
confer
harmon
guidelin
valid
analyt
procedur
includ
specif
abil
unequivoc
determin
analyt
linear
respons
curv
analyt
lower
limit
quantif
concentr
analyt
signal
nois
ratio
precis
accuraci
result
repeat
recoveri
satisfactori
accuraci
precis
stabil
degrad
analyt
aliquot
plasma
dilut
naoh
diazepam
ad
intern
standard
mixtur
extract
ml
dichloromethan
pentan
ratio
vortex
second
upper
organ
phase
transfer
clean
glass
tube
residu
liquid
extract
upper
organ
phase
mixtur
evapor
dryness
dri
residu
dissolv
mobil
phase
centrifug
g
minut
supernat
subject
hplc
analysi
detect
use
ultraviolet
detector
nm
hplc
system
shimpack
mm
mm
revers
phase
column
pack
vpod
shimadzu
corpor
tokyo
japan
use
column
temperatur
set
mobil
phase
mm
ammonium
acet
buffer
ph
acetonitril
vv
flow
rate
ml
per
minut
sampl
analyz
within
valid
stabil
timefram
follow
determin
plasma
concentr
pk
paramet
midazolam
calcul
singlecompartment
analysi
use
pkslover
program
china
pharmaceut
univers
nanj
peopl
republ
china
freeli
avail
menudriven
addin
program
microsoft
excel
written
visual
basic
applic
pk
data
analysi
pk
paramet
calcul
absorpt
rate
constant
ka
elimin
rate
constant
ke
halflif
absorpt
halflif
elimin
volum
distribut
vf
bodi
clearanc
clf
maximum
plasma
concentr
observ
cmax
time
reach
cmax
tmax
area
plasma
concentrationtim
curv
area
first
moment
curv
aumc
mean
resid
time
calcul
use
formula
auc
calcul
use
trapezoid
rule
cl
calcul
formula
clf
doseauc
vf
follow
oral
administr
calcul
use
vf
clfke
equat
effect
xkb
rat
hepat
activ
examin
use
luminesc
assay
accord
manufactur
instruct
briefli
rat
liver
homogen
prepar
describ
reaction
mixtur
ad
microtit
plate
contain
microsom
protein
luciferinipa
substrat
mm
potassium
phosphat
buffer
solut
ph
mix
gentli
plate
preincub
minut
reaction
initi
ad
nadph
mixtur
incub
minut
next
reconstitut
luciferin
detect
reagent
ad
well
reaction
mixtur
mix
plate
shaker
second
plate
incub
minut
activ
examin
luminesc
read
rel
activ
express
fold
chang
control
western
blot
use
investig
regul
effect
xkb
express
rat
liver
briefli
rat
liver
microsom
mg
denatur
minut
centrifug
g
minut
protein
sampl
resolv
sodium
dodecyl
sulfatepolyacrylamid
gel
transfer
onto
polyvinyliden
difluorid
membran
membran
block
one
hour
nonfat
milk
trisbuff
tween
buffer
follow
incub
overnight
respect
primari
antibodi
membran
wash
trisbuff
tween
buffer
incub
secondari
antibodi
one
hour
signal
detect
use
clariti
western
ecl
substrat
biorad
imag
system
quantif
perform
use
imagej
analyz
softwar
media
cybernet
bethesda
md
usa
rel
express
level
rat
liver
microsom
express
ratio
intens
blot
gapdh
data
express
mean
standard
deviat
pk
paramet
compar
use
oneway
analysi
varianc
follow
tukey
multipl
comparison
valu
p
consid
statist
signific
first
predict
molecular
target
xkb
use
webbas
ddicpi
tool
protein
possibl
interact
xkb
tabl
includ
involv
redox
homeostasi
eg
txn
xenobiot
metabol
eg
por
mtap
cell
prolifer
eg
apoptosi
eg
lipid
metabol
eg
ppara
ppard
signal
transduct
eg
rhoa
immun
inflammatori
respons
eg
lck
shown
tabl
david
analysi
identifi
function
cluster
significantli
enrich
enrich
score
target
list
deriv
molecular
dock
calcul
includ
energi
metabol
signal
transduct
vascular
regul
carbohydr
metabol
kyoto
encyclopedia
gene
genom
pathway
found
significantli
enrich
target
list
tabl
particular
pathway
metabol
xenobiot
cyp
enzym
predict
modul
xkb
david
analysi
addit
david
analysi
reveal
overlap
molecular
target
xkb
probucol
tabl
includ
pctp
cetp
prep
sord
cda
ctsb
probucol
antihyperlipidem
drug
origin
develop
treatment
coronari
arteri
diseas
withdrawn
us
market
target
share
xkb
probucol
suggest
xkb
may
promis
agent
lower
blood
lipid
given
predict
number
molecular
target
relat
signal
pathway
possibl
regul
xkb
perform
valid
studi
use
publish
data
extens
search
via
pubm
incept
august
four
publish
paper
report
molecular
target
mechan
action
xkb
reduc
oxid
stress
via
induct
heme
suppress
nadph
oxidas
activ
involv
signal
pathway
human
umbil
vein
endotheli
consist
previou
previou
studi
also
show
xkb
decreas
activ
nadph
oxidas
express
xkb
increas
express
human
umbil
vein
endotheli
cell
injuri
induc
oxid
lowdens
xkb
decreas
mitochondri
superoxid
mitochondri
fragment
express
gtpase
dynaminrel
protein
mitochondri
membran
potenti
data
provid
preliminari
evid
valid
predict
molecular
target
xkb
use
bioinformat
approach
follow
predict
valid
molecular
target
examin
possibl
interact
xkb
midazolam
probe
substrat
ketoconazol
inhibitor
probucol
antihyperlipidem
drug
human
rat
homolog
model
use
discoveri
studio
program
shown
tabl
cdocker
interact
energi
rang
kcalmol
xkb
midazolam
ketoconazol
probucol
xkb
form
hydrogen
bond
activ
site
human
pdb
id
figur
midazolam
ketoconazol
bound
activ
site
human
via
stack
figur
figur
respect
howev
probucol
show
hydrogen
bond
format
stack
charg
interact
human
figur
built
homolog
model
rat
base
crystal
structur
human
pdb
id
sequenc
similar
ident
human
rat
homolog
model
respect
cdocker
interact
energi
rang
kcalmol
tabl
dock
result
show
xkb
bound
activ
site
rat
homolog
model
hydrogen
bond
format
figur
midazolam
readili
dock
activ
site
rat
homolog
model
stack
figur
ketoconazol
bound
hydrogen
bond
format
activ
site
rat
homolog
model
figur
howev
hydrogen
bond
format
stack
charg
interact
probucol
rat
homolog
model
figur
compoundcyp
complex
highest
cdocker
interact
energi
select
twodimension
threedimension
imag
taken
figur
taken
togeth
result
show
xkb
could
bind
activ
site
human
rat
via
hydrogen
bond
format
andor
stack
xkb
may
serv
substrat
andor
inhibitor
two
enzym
predict
admet
properti
xkb
midazolam
ketoconazol
probucol
shown
tabl
aqueou
solubl
valu
log
molar
solubl
xkb
xkb
show
moder
abil
penetr
barrier
good
intestin
absorpt
profil
properti
optim
predict
space
compon
xkb
within
expect
rang
regard
ligand
hepatotox
plasma
protein
bind
level
midazolam
ketoconazol
show
similar
admet
profil
xkb
except
hepatotox
admet
predictor
show
optim
predict
space
valu
midazolam
optim
predict
space
valu
ketoconazol
rang
suggest
compound
might
hepatotox
tabl
probucol
low
aqueou
solubl
low
intestin
absorpt
agreement
data
report
drug
tabl
logp
valu
probucol
oral
bioavail
improv
use
figur
show
repres
chromatogram
blank
rat
plasma
rat
plasma
spike
midazolam
diazepam
result
indic
midazolam
diazepam
separ
complet
assay
condit
endogen
interf
peak
observ
retent
time
calibr
curv
midazolam
rat
plasma
linear
concentr
rang
respect
regress
equat
calibr
curv
obtain
seven
point
midazolam
correl
coeffici
regress
equat
calibr
curv
correl
coeffici
peak
area
ratio
midazolam
diazepam
x
plasma
concentr
midazolam
lower
limit
quantif
establish
determin
concentr
five
spike
calibr
standard
rat
plasma
found
midazolam
respect
taken
togeth
result
show
good
linear
indic
method
use
measur
plasma
sampl
precis
accuraci
method
determin
use
qualiti
control
sampl
three
concentr
midazolam
precis
assay
express
rel
standard
deviat
mean
valu
nomin
concentr
accuraci
express
percentag
mean
valu
calcul
nomin
concentr
result
shown
tabl
valu
within
accept
rang
indic
develop
method
reproduc
accur
reliabl
quantit
determin
midazolam
rat
plasma
mean
extract
recoveri
midazolam
three
concentr
respect
mean
extract
recoveri
three
concentr
respect
recoveri
diazepam
rat
plasma
concentr
stabil
test
perform
low
medium
high
concentr
qualiti
control
sampl
result
shown
tabl
stock
solut
midazolam
stabl
least
day
store
concentr
midazolam
chang
significantli
exposur
sampl
room
temperatur
hour
three
cycl
result
indic
midazolam
stabl
enough
analyz
use
method
within
predetermin
timefram
given
observ
potenti
interact
xkb
rat
examin
effect
xkb
drug
metabol
success
oral
administr
xkb
schedul
use
midazolam
probe
drug
midazolam
wellknown
probe
substrat
human
unclear
appropri
probe
determin
rat
activ
vivo
major
metabolit
midazolam
human
mean
plasma
profil
midazolam
consecut
day
treatment
xkb
shown
group
figur
associ
pk
paramet
list
tabl
result
indic
signific
chang
pk
paramet
midazolam
rat
treat
xkb
day
comparison
vehicletr
rat
treatment
mgkg
xkb
increas
cmax
aumc
midazolam
respect
p
contrast
clf
vf
midazolam
decreas
rat
treat
mgkg
xkb
respect
compar
rat
receiv
vehicl
ka
ke
tmax
mean
resid
time
midazolam
remain
unchang
rat
given
mgkg
xkb
oral
day
data
also
show
oral
administr
xkb
mgkg
significantli
chang
midazolam
increas
oral
administr
xkb
mgkg
significantli
increas
aumc
respect
compar
control
rat
treat
vehicl
similarli
increas
aumc
respect
rat
treat
xkb
mgkg
day
compar
control
rat
compar
vehicletr
rat
ratio
plasma
auc
midazolam
significantli
decreas
rat
treat
oral
xkb
mgkg
howev
treatment
xkb
either
dose
chang
clf
vf
midazolam
rat
addit
compar
normal
salin
soybean
oil
singl
dose
ketoconazol
mgkg
significantli
increas
cmax
midazolam
respect
decreas
vf
clf
midazolam
respect
compar
vehicletr
rat
ratio
plasma
auc
midazolam
significantli
decreas
rat
treat
oral
ketoconazol
mgkg
collect
result
show
xkb
mgkg
significantli
reduc
metabol
midazolam
rat
without
mark
dose
depend
probabl
due
decreas
activ
sinc
total
clearanc
distribut
midazolam
metabolit
alter
xkb
possibl
modul
pathway
xkb
exclud
follow
observ
reduc
metabol
probe
substrat
hepat
activ
measur
use
luminesc
assay
rat
dose
xkb
day
shown
figur
activ
rat
hepat
significantli
inhibit
xkb
comparison
vehicl
group
soybean
oil
p
p
declin
activ
rat
treat
mgkg
xkb
respect
ketoconazol
also
show
significantli
inhibit
activ
reduct
p
compar
salinetr
group
examin
regulatori
effect
xkb
level
express
determin
western
blot
assay
shown
figur
administr
xkb
day
significantli
inhibit
express
rat
liver
compar
vehicl
group
soybean
oil
p
decreas
express
rat
treat
mgkg
xkb
respect
howev
administr
ketoconazol
chang
express
rat
liver
taken
togeth
xkb
potent
inhibitori
effect
express
activ
rat
liver
mechan
downregul
effect
xkb
hepat
rat
unknown
xkb
potent
antioxid
great
potenti
treatment
cvd
molecular
target
effect
drugmetabol
enzym
remain
human
major
cyp
subfamili
metabol
endogen
exogen
modul
activ
express
would
caus
substanti
chang
drug
metabol
clinic
set
present
studi
predict
molecular
target
relat
signal
pathway
regul
xkb
found
xkb
interact
rat
hepat
homolog
model
via
hydrogen
bond
format
found
xkb
increas
cmax
midazolam
inhibit
activ
express
level
rat
treat
xkb
day
find
indic
benefici
effect
xkb
attribut
regul
network
molecular
target
signal
pathway
xkb
regul
drug
metabol
suppress
activ
express
vivo
bioinformat
approach
becom
valuabl
way
predict
interactom
chemic
molecul
use
ddicpi
tool
predict
potenti
target
employ
david
analyz
molecular
target
relat
signal
pathway
regul
xkb
find
show
xkb
modul
number
function
protein
relat
signal
pathway
protein
signal
pathway
import
role
regul
redox
homeostasi
cell
prolifer
apoptosi
energi
metabol
metabol
xenobiot
lipid
carbohydr
metabol
inflammatori
respons
interestingli
xkb
share
number
molecular
target
probucol
initi
develop
antihyperlipidem
drug
treatment
coronari
arteri
diseas
remov
usa
market
found
prolong
qt
overlap
molecular
target
suggest
xkb
regul
target
signal
pathway
probucol
probucol
report
lower
cholesterol
level
blood
increas
rate
lowdens
lipoprotein
catabol
inhibit
cholesterol
synthesi
delay
cholesterol
also
potent
antioxid
suppress
oxid
cholesterol
lowdens
lipoprotein
cholesterol
efflux
regulatori
protein
consid
main
natur
marin
compound
xkb
may
promis
agent
treatment
cvd
potenti
cardiovascular
side
effect
minim
avoid
ddicpi
approach
provid
rapid
inexpens
strategi
predict
potenti
target
identifi
drug
reposit
potenti
evalu
determin
advers
drug
reaction
chemicaldrug
via
molecular
dock
small
compound
across
human
although
webbas
program
sever
limit
may
affect
accuraci
exampl
ddicpi
abl
fulli
reveal
potenti
target
due
lack
human
protein
structur
assess
xkb
shown
potent
antioxid
antiinflammatori
anticanc
effect
preclin
support
predict
xkb
target
multipl
pathway
associ
oxid
stress
redox
homoeostasi
cell
prolifer
apoptosi
order
character
role
xkb
regul
cyp
next
perform
homolog
model
experi
examin
interact
xkb
rat
rat
homolog
model
built
base
human
pdb
id
data
show
rat
homolog
model
share
sequenc
similar
ident
human
report
rat
exhibit
homolog
amino
acid
sequenc
human
differ
may
affect
interact
xkb
rat
inde
find
show
xkb
interact
rat
homolog
model
via
hydrogen
bond
format
locat
activ
site
enzym
howev
interact
xkb
human
locat
activ
site
collect
model
studi
show
xkb
act
substrat
andor
inhibitor
rat
human
howev
extrapol
result
human
bear
mind
share
certain
degre
sequenc
similar
ident
function
valid
alway
need
admet
predictor
show
xkb
moder
water
solubl
oral
absorpt
probucol
low
water
solubl
oral
absorpt
consist
previous
report
predict
admet
profil
show
xkb
might
better
oral
agent
probucol
drug
develop
midazolam
probe
substrat
sed
amnes
anxiolyt
muscl
relax
anticonvuls
properti
human
wide
use
examin
degre
drug
interact
inhibitori
effect
xenobiot
activ
function
via
evalu
urinari
andor
plasma
level
midazolam
main
metabolit
studi
plasma
concentr
midazolam
determin
use
valid
hplc
method
high
specif
linear
precis
accuraci
recoveri
rate
midazolam
test
sampl
show
high
stabil
indic
hplc
method
reliabl
determin
plasma
concentr
midazolam
present
find
show
oral
administr
xkb
kgmg
day
significantli
elev
cmax
midazolam
decreas
clf
xkb
also
show
inhibitori
effect
metabol
midazolam
similar
seen
ketoconazol
vivo
howev
remark
chang
ka
ke
vf
midazolam
rat
treat
xkb
collect
data
strongli
suggest
xkb
decreas
metabol
clearanc
midazolam
rat
notabl
report
midazolam
induc
effect
express
rat
turn
may
affect
metabol
substrat
drug
found
oral
administr
xkb
day
significantli
reduc
express
activ
hepat
via
unknown
mechan
probabl
due
posttranscript
andor
posttransl
modul
target
geneprotein
report
protein
degrad
import
regul
cyp
turnov
posttransl
studi
predict
xkb
might
target
ubiquitin
carboxyltermin
hydrolas
play
import
role
protein
degrad
xkb
might
regul
ubiquitinmedi
protein
degrad
downregul
content
rat
hepat
addit
epigenet
mechan
exclud
exampl
microrna
major
determin
gene
express
posttranscript
level
suppress
gene
express
mrna
cleavag
translat
moreov
report
express
rat
hepat
predispos
regul
nuclear
transcript
factor
nuclear
may
also
involv
regulatori
effect
xkb
express
rat
data
import
implic
drug
develop
xkb
use
lead
compound
exampl
xkb
may
profound
therapeut
effect
due
interact
potenti
multipl
target
howev
multitarget
agent
may
also
result
side
effect
due
unwant
bind
toxicityassoci
target
eg
herg
potenti
interact
xkb
may
lead
unfavor
drug
interact
addit
short
elimin
halflif
xkb
may
neg
affect
concentr
site
action
compromis
therapeut
effect
clinic
practic
therefor
find
provid
clue
xkbbase
drug
develop
clinic
use
includ
structur
modif
nanotechnologybas
formul
minim
avoid
potenti
side
effect
prolong
elimin
halflif
achiev
therapeut
concentr
site
action
summari
found
medicin
effect
xkb
could
ascrib
modul
network
function
protein
relat
signal
pathway
xkb
significantli
inhibit
metabol
midazolam
rat
vivo
via
reduct
activ
express
hepat
find
suggest
xkb
may
behav
substrat
andor
inhibitor
probabl
alter
pk
profil
coadminist
drug
metabol
bodi
molecular
target
modul
effect
xkb
human
cyp
need
examin
function
valid
futur
